UPDATE: Stifel Nicolaus Raises PT to $118 on Allergan on Solid 2013 Outlook
Posted on February 06, 2013 at 13:48 PM EST
Stifel Nicolaus maintained Allergan (NYSE: AGN ) with a Buy rating and raised the price target from $110.00 to $118.00. Stifel Nicolaus noted, "2013 guidance was robust, with product sales of $5.9-6.2bn (Consensus at high end of range) and EPS between $4.75-4.83 (15-17% growth, Consensus $4.74). Notably, guidance excluded